and Their Natural Flavonoid Compounds in the Treatment of Ovarian Cancer: A Review

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Jul 14

PMID 37446743

Authors

Jiaying Cai

Qichao Hu

Zhelin He

Xiaoyan Chen

Jian Wang

Xiang Yin

Xiao Ma

Jinhao Zeng

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is one of the most common types of cancer in women with a high mortality rate, and the treatment of OC is prone to high recurrence rates and side effects. (SB) is a herbal medicine with good anti-cancer activity, and several studies have shown that SB and its flavonoids have some anti-OC properties. This paper elucidated the common pathogenesis of OC, including cell proliferation and cell cycle regulation, cell invasion and metastasis, apoptosis and autophagy, drug resistance and angiogenesis. The mechanisms of SB and its flavonoids, wogonin, baicalein, baicalin, Oroxylin A, and scutellarein, in the treatment of OC, are revealed, such as wogonin inhibits proliferation, induces apoptosis, inhibits invasion and metastasis, and increases the cytotoxicity of the drug. Baicalein also inhibits vascular endothelial growth factor (VEGF) expression etc. Analyzing their advantages and disadvantages in treating OC provides a new perspective on the role of SB and its flavonoids in OC treatment. It serves as a resource for future OC research and development.

Citing Articles

Modulating NLRP3 Inflammasomes in Idiopathic Pulmonary Fibrosis: A Comprehensive Review on Flavonoid-Based Interventions.

Vithalkar M, Pradhan S, Sandra K, Bharath H, Nayak Y Cell Biochem Biophys. 2025; .

PMID: 39966334 DOI: 10.1007/s12013-025-01696-4.

Network pharmacology-based strategy to reveal the mechanism of pinocembrin against ovarian cancer.

Wang G, Cheng J, Yao M, Li J, Chen T, Zhang J Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39361173 DOI: 10.1007/s00210-024-03492-y.

The Effect of the Extraction Conditions on the Antioxidant Activity and Bioactive Compounds Content in Ethanolic Extracts of Root.

Dzieciol M, Wala K, Wroblewska A, Janda-Milczarek K Molecules. 2024; 29(17).

PMID: 39275001 PMC: 11397618. DOI: 10.3390/molecules29174153.

Mechanism of baicalein in treatment of castration-resistant prostate cancer based on network pharmacology and cell experiments.

Dou B, Cui Y, Zhou Q, Fu J, Zhou Y, Zhang X Front Pharmacol. 2024; 15:1397703.

PMID: 38989144 PMC: 11233443. DOI: 10.3389/fphar.2024.1397703.

Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?.

Andres C, Perez de la Lastra J, Munguira E, Juan C, Perez-Lebena E Int J Mol Sci. 2024; 25(11).

PMID: 38892287 PMC: 11172677. DOI: 10.3390/ijms25116099.

References

Gatti L, Zunino F . Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005; 111:127-48. DOI: 10.1385/1-59259-889-7:127. View

Zhong L, Pan Y, Shen J . FBXW7 inhibits invasion, migration and angiogenesis in ovarian cancer cells by suppressing VEGF expression through inactivation of β-catenin signaling. Exp Ther Med. 2021; 21(5):514. PMC: 8005732. DOI: 10.3892/etm.2021.9945. View

Fu W, Wang J, Yu L, Zhao L, Lu N, You Q . Synthesis and biological evaluation of 7-O-modified oroxylin A derivatives. Bioorg Med Chem Lett. 2011; 22(2):1118-21. DOI: 10.1016/j.bmcl.2011.11.117. View

Adkins D, Ley J, Neupane P, Worden F, Sacco A, Palka K . Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol. 2019; 20(9):1295-1305. DOI: 10.1016/S1470-2045(19)30405-X. View

Duan L, Yan Y, Wang G, Xing Y, Sun J, Wang L . ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6). J BUON. 2020; 25(5):2279-2286. View

Mu R, Qi Q, Gu H, Wang J, Yang Y, Rong J . Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. Mol Carcinog. 2009; 48(12):1159-69. DOI: 10.1002/mc.20570. View

Chung Y, Kim S, Hong J, Lee J, Lee N, Lee Y . Overexpression of HER2/HER3 and clinical feature of ovarian cancer. J Gynecol Oncol. 2019; 30(5):e75. PMC: 6658608. DOI: 10.3802/jgo.2019.30.e75. View

Ren G, Chen H, Zhang M, Yang N, Yang H, Xu C . Pharmacokinetics, tissue distribution and excretion study of Oroxylin A, Oroxylin A 7-O-glucuronide and Oroxylin A sodium sulfonate in rats after administration of Oroxylin A. Fitoterapia. 2020; 142:104480. DOI: 10.1016/j.fitote.2020.104480. View

Yousif N . Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int. 2013; 38(1):85-91. DOI: 10.1002/cbin.10184. View

10.

Zhou Y, Liu Q, Liu C, Lin L . Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by activating caspases and Bcl-2 family proteins. Tumour Biol. 2015; 36(7):5333-9. DOI: 10.1007/s13277-015-3194-8. View

11.

Yan H, Xin S, Wang H, Ma J, Zhang H, Wei H . Baicalein inhibits MMP-2 expression in human ovarian cancer cells by suppressing the p38 MAPK-dependent NF-κB signaling pathway. Anticancer Drugs. 2015; 26(6):649-56. DOI: 10.1097/CAD.0000000000000230. View

12.

Hussain I, Waheed S, Ahmad K, Pirog J, Syed V . Scutellaria baicalensis targets the hypoxia-inducible factor-1α and enhances cisplatin efficacy in ovarian cancer. J Cell Biochem. 2018; 119(9):7515-7524. DOI: 10.1002/jcb.27063. View

13.

Bie B, Sun J, Guo Y, Li J, Jiang W, Yang J . Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma. Biomed Pharmacother. 2017; 93:1285-1291. DOI: 10.1016/j.biopha.2017.07.068. View

14.

Zhang Q, Li J, Jiang K, Wang R, Ge J, Yang H . CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics. 2020; 10(23):10619-10633. PMC: 7482823. DOI: 10.7150/thno.44871. View

15.

Kavandi L, Lee L, Bokhari A, Pirog J, Jiang Y, Ahmad K . The Chinese herbs Scutellaria baicalensis and Fritillaria cirrhosa target NFκB to inhibit proliferation of ovarian and endometrial cancer cells. Mol Carcinog. 2013; 54(5):368-78. DOI: 10.1002/mc.22107. View

16.

Xu X, Lai Y, Hua Z . Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2018; 39(1). PMC: 6340950. DOI: 10.1042/BSR20180992. View

17.

Chen S, Cooper M, Jones M, Madhuri T, Wade J, Bachelor A . Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals. Cell Biol Toxicol. 2010; 27(2):133-47. DOI: 10.1007/s10565-010-9176-0. View

18.

Davies B, Brown P, East N, Crimmin M, Balkwill F . A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993; 53(9):2087-91. View

19.

Imam J, Plyler J, Bansal H, Prajapati S, Bansal S, Rebeles J . Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One. 2013; 7(12):e52397. PMC: 3528651. DOI: 10.1371/journal.pone.0052397. View

20.

Hernandez L, Kim M, Noonan A, Sagher E, Kohlhammer H, Wright G . A dual role for Caspase8 and NF-B interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival. Cell Death Discov. 2017; 1:15053. PMC: 5198842. DOI: 10.1038/cddiscovery.2015.53. View